{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:13:02Z","timestamp":1763057582665},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T00:00:00Z","timestamp":1291075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9753-3","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T21:02:36Z","timestamp":1291064556000},"page":"605-612","source":"Crossref","is-referenced-by-count":9,"title":["Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Zhengbo","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"9753_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225\u201349.","journal-title":"CA Cancer J Clin"},{"key":"9753_CR2","volume-title":"Lung cancer: principles and practice","author":"H Pass","year":"2000","unstructured":"Pass H, et al. Lung cancer: principles and practice. Philadelphia: Lipponcott Williams & Wilkins; 2000."},{"key":"9753_CR3","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1200\/JCO.2009.26.6171","volume":"27","author":"NJ Petrelli","year":"2009","unstructured":"Petrelli NJ, et al. Clinical cancer advances 2009:major research advances in cancer treatment, prevention, and screening-A reports from the american society of clinical oncology. J Clin Oncol. 2009;27:6052\u201369.","journal-title":"J Clin Oncol"},{"key":"9753_CR4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","volume":"311","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"1995","unstructured":"Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311:899\u2013909.","journal-title":"Br Med J"},{"key":"9753_CR5","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","volume":"26","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"2008","unstructured":"Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized clinical trials. J Clin Oncol. 2008;26:4617\u201325.","journal-title":"J Clin Oncol"},{"key":"9753_CR6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, et al. Eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92\u20138.","journal-title":"N Engl J Med"},{"key":"9753_CR7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095\u2013103.","journal-title":"J Clin Oncol"},{"key":"9753_CR8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354\u201362.","journal-title":"J Clin Oncol"},{"key":"9753_CR9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589\u201397.","journal-title":"J Clin Oncol"},{"key":"9753_CR10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","volume":"366","author":"N Thatcher","year":"2005","unstructured":"Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527\u201337.","journal-title":"Lancet"},{"key":"9753_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123\u201332.","journal-title":"N Engl J Med"},{"key":"9753_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jjco\/hyn118","volume":"39","author":"JM Sun","year":"2008","unstructured":"Sun JM, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol. 2008;39:27\u201332.","journal-title":"Jpn J Clin Oncol"},{"key":"9753_CR13","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/JTO.0b013e3181bbf223","volume":"4","author":"G Nicolas","year":"2009","unstructured":"Nicolas G, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009;4:1544\u20139.","journal-title":"J Thorac Oncol."},{"key":"9753_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"9753_CR15","doi-asserted-by":"crossref","unstructured":"Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176\u2013181.","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"9753_CR16","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","volume":"27","author":"GA Christopher","year":"2009","unstructured":"Christopher GA, et al. American society of clinical oncology clinical practice. Guideline update on chemotherapy for stage IV non\u2013small-cell lung cancer. J Clin Oncol. 2009;27:6251\u201366.","journal-title":"J Clin Oncol"},{"key":"9753_CR17","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1067\/msy.2002.119796","volume":"131","author":"I Yoshino","year":"2002","unstructured":"Yoshino I, et al. A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer. Surgery. 2002;131:S242\u20138.","journal-title":"Surgery"},{"key":"9753_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","volume":"39","author":"E Massarelli","year":"2003","unstructured":"Massarelli E, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55\u201361.","journal-title":"Lung Cancer"},{"key":"9753_CR19","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2008.17.5844","volume":"27","author":"MD Maio","year":"2009","unstructured":"Maio MD, et al. Meta-Analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non\u2013small-cell lung cancer. J Clin Oncol. 2009;27:1836\u201343.","journal-title":"J Clin Oncol"},{"key":"9753_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2009.12.015","volume":"70","author":"HS Kim","year":"2010","unstructured":"Kim HS, et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 2010;70:71\u20136.","journal-title":"Lung Cancer"},{"key":"9753_CR21","doi-asserted-by":"crossref","unstructured":"Smit EF, et al. A radomized phase II Study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC)-NVALT7. J Clin Oncol. 2008; 26:436\u00a0s, (abstract 8050).","DOI":"10.1200\/jco.2008.26.15_suppl.8050"},{"key":"9753_CR22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01243894-200607000-00008","volume":"1","author":"YM Chen","year":"2006","unstructured":"Chen YM, et al. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol. 2006;1:545\u201350.","journal-title":"J Thorac Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9753-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9753-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T17:09:03Z","timestamp":1559840943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9753-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":22,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9753"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9753-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}